Poststroke Depression, An Underrated Clinical Dilemma: 2022.

Autor:	Jamil A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Csendes D; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Gutlapalli SD; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Prakash K; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Swarnakari KM; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Bai M; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Manoharan MP; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Raja R; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Desai A; Internal Medicine Clinical Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.; Internal Medicine, University of California Riverside School of Medicine, Riverside, USA., Desai DM; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Arcia Franchini AP; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Dec 26; Vol. 14 (12), pp. e32948. Date of Electronic Publication: 2022 Dec 26 (Print Publication: 2022).
DOI:	10.7759/cureus.32948
Abstrakt:	It is known that the majority of patients are prone to develop depression following a stroke. Several biological factors, including the disruption of the hypothalamic and adrenal axis and changes in cortisol and interleukin 6 (IL6), are said to have an essential role in its development. Magnetic resonance imaging (MRI) scans point toward white matter lesions and lacunar infarcts as the primary pathological culprit. People affected by poststroke depression (PSD) are more likely to commit suicide or develop another ischemic event after the initial episode, which can likely increase the mortality related to PSD and stroke. Selective serotonin reuptake inhibitors (SSRIs) are the mainstay of treatment for PSD. However, it has a poor safety profile and is not very productive, making the use of SSRIs controversial, and further studies are required to prove its benefits concerning PSD. This literature review discusses the importance of PSD, how it impacts the quality of life of people affected by stroke, and its treatment. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Jamil et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu